Volltextsuche nutzen

B O O K SCREENER

Aktuelle Veranstaltungen

Events
  • versandkostenfrei ab € 30,–
  • 11x in Wien, NÖ und Salzburg
  • 6 Mio. Bücher
Menü
Malignant Liver TumorsOverlay E-Book Reader

Malignant Liver Tumors

Current and Emerging Therapies

Malignant Liver TumorsOverlay E-Book Reader
E-Book
(EPUB mit drm)
269,99
E-Book
(EPUB mit drm)
269,99
inkl. gesetzl. MwSt.
EPUB (mit DRM) sofort downloaden
Downloads sind nur in Österreich möglich!
Leitfaden zu E-Books
In den Warenkorb
Click & Collect
Artikel online bestellen und in der Filiale abholen.
Artikel in den Warenkorb legen, zur Kassa gehen und Wunschfiliale auswählen. Lieferung abholen und bequem vor Ort bezahlen.
Derzeit in keiner facultas Filiale lagernd. Jetzt online bestellen!
 
This comprehensive and critical review of current and established
treatment modalities for malignant liver tumors is designed to help
you sort through the proliferation of competitive approaches and
choose the best treatment options for your patient. Dr. Clavien and
his contributors consider all the options - radiological,
surgical, pharmaceutical, and emerging/novel therapies - and
help you find ...
Beschreibung
This comprehensive and critical review of current and established
treatment modalities for malignant liver tumors is designed to help
you sort through the proliferation of competitive approaches and
choose the best treatment options for your patient. Dr. Clavien and
his contributors consider all the options - radiological,
surgical, pharmaceutical, and emerging/novel therapies - and
help you find the best single or combined therapy.

Building on the success of the previous edition, this extremely
thorough revision:

* features a new section on Guidelines for Liver Tumors, where
you will find specific strategies for treating common liver
malignancies; the guidelines were prepared by the Associate Editors
and take into account national and international society
guidelines

* reflects actual practice by taking a multidisciplinary
approach, with contributions from international experts who have
extensive experience with this patient population

* achieves comprehensive and balanced coverage by having each
chapter reviewed by the Editor, Deputy Editor, two Associate
Editors, and at least one external reviewer

* includes 16 new chapters that cover liver anatomy, histologic
changes in the liver, epidemiology and natural history of HCC, CCC
and colorectal liver metastases, strategies of liver resection, and
economic aspects as well as novel therapies

* facilitates the kind of daily interaction among hepatologists,
hepatic surgeons, medical oncologists, radiotherapists, and
interventional radiologists that is essential when treating
patients with complex liver malignancies

In 44 chapters organized into six major sections, the book
covers the full range of liver tumors. The perfect blend of
evidence and experience, Malignant Liver Tumors: Current and
Emerging Therapies, 3rd Edition, illuminates the
path to better patient care.

Besprechung
"This book is a worthy update. A significant amount of
material has been added, including the new section. It definitely
justifies replacing the old edition and will be a valuable resource
for physicians of all disciplines involved in the care of these
patients." (Doody's, 23 March 2012)

"The third edition of Malignant Liver Tumors is well written
with broad coverage of primary and metastatic liver tumors with a
particular emphasis on current and emerging treatment. Consisting
of up-to-date and comprehensive reviews on management of hepatic
neoplasms, this book will not only be instructive to liver
surgeons, trainees, and fellows, but also be valuable to
hepatologists, oncologists, and interventional radiologists who
form the multidisciplinary team to manage patients with these
tumors." (Gastroenterological, 1 March 2011)

Über Pierre-Alain Clavien, Stefan Breitenstein, Jacques Belghiti, Ravi S. Chari, Josep M. Llovet, Chung-Mau Lo, Michael A. Morse, Tadatoshi Takayama, Jean-Nicolas Vauthey

Editor-in-Chief:

Pierre-Alain Clavien

Department of Visceral and Transplant Surgery, University Hospital
Zurich, Switzerland



Associate Editors:

Tadatoshi Takayama, Second Department of Surgery, Faculty of
Medicine, University of Tokyo, Japan

CM Lo, Liver Transplant Centre, Queen Mary Hospital, 102
Pokfulam Road, Hong Kong

R. Chari, Associate Professor of Surgery and Cancer
Biology, Division Chief of Hepatobillary Surgery and Liver
Transplantation, Staff Surgeon, Veterans Affairs Medical Center,
Vanderbilt University Medical Center, Nashville, USA

M. Morse, Associate Professor, Duke University Medical
School, Durham, USA

J. Llovet, Barcelona-Clínic Liver Cancer Group,
Liver Unit, Institut d'Investigacions Biomédiques August Pi I
Sunyer, Hospital Clínic, University of Barcelona, Catalonia,
Spain